- Home
- SEAT vs PCRX Comparison
SEAT vs PCRX Comparison
Compare SEAT & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SEAT
- PCRX
- Stock Information
- Founded
- SEAT 2001
- PCRX 2006
- Country
- SEAT United States
- PCRX United States
- Employees
- SEAT N/A
- PCRX N/A
- Industry
- SEAT Industrial Machinery/Components
- PCRX Biotechnology: Pharmaceutical Preparations
- Sector
- SEAT Industrials
- PCRX Health Care
- Exchange
- SEAT Nasdaq
- PCRX Nasdaq
- Market Cap
- SEAT 622.1M
- PCRX 1.2B
- IPO Year
- SEAT N/A
- PCRX 2011
- Fundamental
- Price
- SEAT $4.48
- PCRX $26.59
- Analyst Decision
- SEAT Strong Buy
- PCRX Buy
- Analyst Count
- SEAT 10
- PCRX 10
- Target Price
- SEAT $6.73
- PCRX $29.30
- AVG Volume (30 Days)
- SEAT 1.1M
- PCRX 892.8K
- Earning Date
- SEAT 03-04-2025
- PCRX 02-27-2025
- Dividend Yield
- SEAT N/A
- PCRX N/A
- EPS Growth
- SEAT N/A
- PCRX N/A
- EPS
- SEAT N/A
- PCRX N/A
- Revenue
- SEAT $774,076,000.00
- PCRX $694,957,000.00
- Revenue This Year
- SEAT $10.17
- PCRX $5.14
- Revenue Next Year
- SEAT $4.02
- PCRX $2.44
- P/E Ratio
- SEAT N/A
- PCRX N/A
- Revenue Growth
- SEAT 13.91
- PCRX 4.40
- 52 Week Low
- SEAT $3.24
- PCRX $11.16
- 52 Week High
- SEAT $6.41
- PCRX $31.67
- Technical
- Relative Strength Index (RSI)
- SEAT 49.56
- PCRX 77.75
- Support Level
- SEAT $4.13
- PCRX $25.06
- Resistance Level
- SEAT $4.78
- PCRX $27.10
- Average True Range (ATR)
- SEAT 0.26
- PCRX 1.45
- MACD
- SEAT -0.08
- PCRX 0.28
- Stochastic Oscillator
- SEAT 26.67
- PCRX 86.23
About SEAT Vivid Seats Inc.
Vivid Seats Inc is an online ticket marketplace for connecting fans to live events and artists. It is the official ticketing partner of brands in the entertainment industry providing tickets for sports, concerts, theatres, and comedy events in the United States, Canada and Japan. It operates in two segments namely marketplace and resale.
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company has three commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve.